89bio, Inc. (ETNB) Stock Analysis & Investment Frameworks
89bio, Inc. (ETNB) stock analysis on Invetso. Review 89bio, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
89bio, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
89bio, Inc. Key Financial Metrics
- Market Cap: $2.20B
- Revenue: $N/A
- ROE: -78.34%
- ROIC: -86.77%
- Dividend Yield: N/A
About 89bio, Inc.
Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia. Founded in 2018, 89bio, Inc. maintains its corporate headquarters in San Francisco, California.
89bio, Inc. Investment Frameworks
Invetso analyzes 89bio, Inc. (ETNB) across the following frameworks:
- 89bio, Inc. 10Y Growth Potential
- 89bio, Inc. Scenario Analysis
- 89bio, Inc. Risks & Opportunities
- 89bio, Inc. Economic Moat
- 89bio, Inc. Business Model
- 89bio, Inc. Management
- 89bio, Inc. SWOT Analysis
- 89bio, Inc. Porter's 5 Forces
- 89bio, Inc. PESTLE Analysis
- 89bio, Inc. ESG Analysis